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Chemokine (C–C motif) ligand 19 (CCL19) is a critical regulator of the induction of T cell
activation, immune tolerance, and inflammatory responses during continuous immune
surveillance, homeostasis, and development. Migration of CC-chemokine receptor 7
(CCR7)-expressing cells to secondary lymphoid organs is a crucial step in the onset
of adaptive immunity, which is initiated by a complex interaction between CCR7 and
its cognate ligands. Recent advances in knowledge regarding the response of the
CCL19-CCR7 axis to viral infections have elucidated the complex network of interplay
among the invading virus, target cells and host immune responses. Viruses use various
strategies to evade or delay the cytokine response, gaining additional time to replicate
in the host. In this review, we summarize the impacts of CCL19 and CCR7 expression
on the regulation of viral pathogenesis with an emphasis on the corresponding signaling
pathways and adjuvant mechanisms. We present and discuss the expression, signaling
adaptor proteins and effects of CCL19 and CCR7 as these molecules differentially
impact different viral infections and viral life cycles in host homeostatic strategies. The
underlying mechanisms discussed in this review may assist in the design of novel agents
to modulate chemokine activity for viral prevention.
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INTRODUCTION
CCL19 and its receptor CCR7 control a diverse array of migratory events in adaptive immunity
following antigen encounter by immunocytes. Recently, some rules governing the mechanisms
of the CCL19-CCR7 axis in directing lymphocyte homing and encountering viruses have been
clarified in vitro (Comerford et al., 2006; de Paz et al., 2007; Jafarnejad et al., 2017). In vivo,
both the host’s antiviral and adjuvant-based immune responses are regulated by interactions
among viral proteins, chemokine receptors and their downstream adaptor components.
Changes in the bioavailability of CCR7/ligands (CCL19 and CCL21) may modulate the
immunopathogenesis pathways of the host, thereby altering virus invasion (Comerford et al., 2013;
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Steen et al., 2014). Hence, we systematically evaluated the
contributions of CCL19 and CCR7 expression polymorphisms,
signal transduction and CCL19-based adjuvant mechanisms in
viral infections.
CCL19 and CCL21 have a conserved tetra-cysteine motif
but only share 32% amino acid identity. Structurally, CCL21
differs from CCL19 because it has a uniquely long C-terminal
tail containing an extra 37 amino acids (6 cysteine residues)
that are highly positively charged and capable of binding
glycosaminoglycans (GAGs) (Nagira et al., 1997; Steen et al.,
2014). CCL19 is secreted by mature dendritic cells (mDCs),
while CCL21 is secreted from the endothelium of afferent
lymphatic vessels (this has been shown in mice, but evidence
in humans is lacking), and both are predominantly secreted
by the lumen of high endothelial venules, the stromal cells of
the draining lymph node and the spleen (Steen et al., 2014;
Wang et al., 2018). Due to their differential structures and
expression patterns, CCL19 and CCL21 display different binding
affinities for specific heparin or heparan sulfate, and distinct
signaling responses are required for in vivo functions (Rot and
von Andrian, 2004; de Paz et al., 2007; Raju et al., 2015). CCR7
was the first identified lymphocyte-specific G-protein-coupled
receptor (GPCR) with seven transmembrane spanning alpha
helices (Birkenbach et al., 1993). CCR7 is expressed on double
negative and single positive thymocytes, including naïve T cells,
central memory T cells, regulatory T cells, naïve B cells, semi-
mature/mature DCs and NK cells, and a minority of tumor cells,
and it acts as a key regulator guiding homeostatic lymphocytes
to secondary lymphoid organs (Ohl et al., 2004; Comerford et al.,
2013; Hauser and Legler, 2016; Wang et al., 2018; Laufer et al.,
2019). The CCR7-ligand axis carries out the following three
fundamental “cellular reflexes”: message acquisition, semantic
extraction and initiation of cell responses (Bardi et al., 2001; Rot
and von Andrian, 2004; Griffith et al., 2014). Chemokine receptor
internalization due to binding with a chemokine helps regulate
chemokine activities (Rot and von Andrian, 2004). CCL19 is
the only chemokine known to effectively stimulate β-arrestin-
mediated CCR7 phosphorylation and internalization, leading to
receptor desensitization and antigen-presenting dendritic cell
(DC) migration (Bardi et al., 2001; Tian et al., 2014; Anderson C.
et al., 2016). In particular, CCL19 displays obvious concentration-
and time-dependent internalization in CD4+ and CD8+ T
cells, which differs from CCL21 (Hjortø et al., 2016). Both
ligands are able to activate G-protein signaling and elicit 3D
chemotaxis and Ca2+ flux, but CCL19 has been shown to be
relatively more potent (Bardi et al., 2001; Steen et al., 2014;
Hjortø et al., 2016) (Figure 1).
Chemokines constitute a class of cytokines that control
immunocyte migration to infection and inflammation sites in
many biological processes. In different virus–host interactions,
chemokine receptors may play a sensory function in the
immune system, resulting in the production of the characteristic
fingerprints of chemokines (Chensue, 2001; Alcami, 2003). The
chemokine system can be mimicked by viruses, and viral proteins
can act as antagonists or inappropriate agonists to use host
chemokine receptors as modes of cellular invasion (Rot and von
Andrian, 2004). For instance, human immunodeficiency virus
type 1 (HIV-1) masquerades as a “chemokine” to promote its
fusion with target cells (Murphy, 2001). Additionally, poxviruses
and herpesviruses encode homologs of chemokine receptors that
are expressed on their target cells, allowing the host chemokines
to direct the infected cells to remote sites for viral dissemination
(Alcami, 2003). Based on the essential roles of the CCL19-CCR7
axis in organizing immunological and inflammatory responses,
we summarize in this review its pathogenic roles in some viral
infection conditions, such as infections by HIV-1 (Wilflingseder
et al., 2004; Cameron et al., 2010; Damås et al., 2012; Hong et al.,
2012; Ramirez et al., 2014; Anderson J.L. et al., 2016), scrapie virus
(Kim et al., 2018), respiratory syncytial virus (RSV) (Le Nouën
et al., 2011; Inchley et al., 2013; Alturaiki et al., 2018), Epstein–
Barr virus (EBV) (Ehlin-Henriksson et al., 2009; Dunham et al.,
2017; Wu et al., 2017), influenza virus (Debes et al., 2004; Piqueras
et al., 2006), dengue virus (DENV) (Wu et al., 2009, 2011; Hsu
et al., 2015), hepatitis B virus (HBV) (Zhang et al., 2009; Cao et al.,
2014), and West Nile virus (WNV) (Bardina et al., 2017). The
CCL19-CCR7 axis also plays a role in vaccine-based protection
against multiple viruses, such as HIV-1 (Hu et al., 2013), herpes
simplex virus 1 (HSV-1) (Lee et al., 2003; Toka et al., 2003), HSV-
2 (Yan et al., 2015), hepatitis C virus (HCV) (Hartoonian et al.,
2014), and pseudorabies virus (Han et al., 2009). In addition, the
CCL19-CCR7 interaction helps immune cells release antiviral-
related cytokines (e.g., IFN-γ and IL-4), which promote T cell
proliferation and antigen uptake by DC (Hu et al., 2013, 2017).
For many years, the focus on prophylactic vaccines aimed
to elicit robust neutralizing antibody (Ab) responses. However,
increasing evidence suggests that T cell-mediated immunity also
plays a critical role in controlling persistent viral infections,
such as HIV-1, cytomegalovirus (CMV), and HCV infections
(Kallas et al., 2016). Recently, various promising prophylactic
vaccines in conjunction with adjuvant cytokines or chemokines,
such as CCL19, have been investigated to enhance virus-specific
cellular immune responses through cytokine polyfunctionality.
For future therapeutic initiatives, it is important to understand
the roles of the CCL19/CCR7 axis in modulating immune cell
migration and activation to potentially differentiate the good and
bad effects. In this review, we evaluate the functional efficacies of
CCL19 and CCR7 in viral infection and prevention, which may
facilitate the development of more potent, durable and safe T
cell-based anti-virus pharmaceuticals or vaccines.
DECREASED CCR7 EXPRESSION AND
LESS EFFICIENT CHEMOTACTIC
RESPONSES TO CCL19 IN THE
CONTEXT OF VIRAL INFECTIONS
CCR7+ immune effector cells become dysfunctional during
some viral infections, followed by the decreased expression
of CCR7 during adaptive immune responses (Förster et al.,
2008). CCR7 presents as a defining factor for non-polarized
central (CCR7+) and polarized effector memory (CCR7−) T
cells (Unsoeld et al., 2002). CCR7 is expressed at high levels
on naïve and central memory T cells and enables homeostasis
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FIGURE 1 | Schematic of CCR7 and its ligands. CCL19, CCL21 and tailless CCL21 bind CCR7, a 7-transmembrane receptor. Binding of receptor/ligands results in
GPCR activation and consequent internalization, followed by a decrease in the surface-exposed receptor and activation of certain intracellular pathways. GAG,
glycosaminoglycan.
T cell subsets to recirculate and home to T cell areas in
lymphoid organs, such as the white pulp areas of the spleen
and lymph nodes (Rot and von Andrian, 2004; Schaerli and
Moser, 2005). During murine lymphocytic choriomeningitis
virus (LCMV) infection, CCR7 is down-regulated on virus-
specific CD8+ effector T cells in vivo (Potsch et al., 1999). The
down-regulation of CCR7 expression on virus-specific CD8+
effector T cells renders the cells unresponsive to chemokines
from secondary lymphoid tissues, which limits T cell homing.
It has been speculated that the exclusion of CD8+ effector T
cells from the T-zone may represent an important mechanism
protecting professional antigen-presenting cells (APCs) against
cytotoxic T cell attacks and, thus, preventing a premature
decline in immune responses. During HIV-1 infection, the
CCL19/CCR7 axis assists with establishing a latent infection. The
CCR7 expression pattern is strongly correlated with increased
HIV-1 viral reservoirs and is associated with chronic HIV-1
infection. Stimulation of HIV-1-infected primary CD4+ T cells
with CCL19 results in the enhancement of both the motility
of CCR7-dependent T cells and the permissiveness of resting
memory T cells, leading to the efficient propagation of HIV-
1 (Saleh et al., 2007; Hayasaka et al., 2015). In addition,
the HIV-1 accessory protein Vpu induces the down-regulation
of CCR7 expression on the surface of HIV-1-infected CD4+
T cells (Ramirez et al., 2014). Consistently, a clinical study
showed that HIV-1-infected individuals lack CCR7 expression
on natural killer (NK) cells (Hong et al., 2012). An HIV-1
and CMV coinfection study demonstrated that most (>70%)
CD8+ effector T cells have a CCR7− phenotype in both the
blood and lymph nodes (Ellefsen et al., 2002). Furthermore,
mechanistic studies have shown that HIV-1 gp120 can mimic
chemokine sequences and significantly promote chemokine
receptor-dependent CD4+ target-cell migration to remote lymph
nodes, which likely leads to enhanced viral dissemination
(Murphy, 2001; Hayasaka et al., 2015).
Similarly, two previous studies shows that mice infected
with scrapie virus (ME7 strain) have been shown to exhibit an
impaired splenic white pulp structure and markedly diminished
T-zone areas in the spleen due to the decreased splenic expression
of CCL19 and CCL21 (Kim et al., 2016, 2018). Furthermore,
decreased expression of T cell homing chemokines CCL19 and
CCL21 resulted in a partial failure in CD4+ T cell recruitment
to the spleen and expression of the memory marker CD44 on
CCR7± CD4+ T cells was decreased in scrapie virus (ME7
strain)-infected mice compared to that in control mice (Table 1).
Finally, high levels of the cellular prion protein [PrP(C)] and
accumulated PrP(Sc) expressed by follicular DCs were detected
in the ME7-infected spleens. During the infection of respiratory
viruses, such as human respiratory syncytial virus (HRSV),
human metapneumovirus (HMPV) and human parainfluenza
virus type 3 (HPIV3), can induce incomplete or short-lived
virus-specific immunity. These viruses can produce symptomatic
reinfections throughout life without undergoing significant
antigenic changes. As a class of professional presentation
cells, DCs can provide antigen presentation in the context
of viral infection. However, human monocyte-derived DCs
(mo-DCs) stimulated with HRSV, HMPV, or HPIV3 show an
inefficient increase in CCR7 expression unless a secondary
stimulation with lipopolysaccharide (LPS) or a cocktail of
proinflammatory cytokines is presented. In contrast, HRSV
and HMPV infections induce less CCR7 expression and less
efficient DC migration in response to CCL19 than HPIV3. The
low expression of CCR7 mediates the inefficient migration of
HRSV- and HMPV-stimulated DCs to lymphoid organs and
causes impaired adaptive responses to these viruses, ultimately
leading to abundant virus replication and tissue damage, thus
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TABLE 1 | Expression of CCL19 and its receptor CCR7 during viral infections.
Virus Species Early stage Middle stage End stage Outcome References
HIV-1 Human – – CCR7+ CD45RA+
CD4+ T cells ↓
Chronic infection/latency Hong et al., 2012;
Ramirez et al., 2014
Scrapie
virus
Mice Days 1–50: CCR7+
CD4+ T cells were
normal
Days 51–130: CCR7+
CD4+ T cells were
normal
Days 131–200: CCR7+
CD4+ T cells ↓
Diminished T-zone area in the
spleen and increased germinal
center reactions.
Kim et al., 2016, 2018
RSV Human – – CCR7+ mo-DCs ↓ Less DCs migrate to lymphatic
tissue
Le Nouën et al., 2011;
Inchley et al., 2013
Mouse DCs Day 1: CCL13↑,
CCL12, CCL19, and
CCL21
Day 2: CCL13↑,
CCL12, CCL19, and
CCL21
Days 4 and 7: CCL12,
CCL13, CCL19↑, and
CCL21
Unknown Alturaiki et al., 2018
EBV Tonsillar B
cells
Day 2: CCR7↓,
CXCR5↓, CCR9↑,
CCR2↑, CCL19↑
(2.9-fold), and
CCL20↑ (4.1-fold)
Day 7: CCR7↓,
CXCR5↓, CCR6↓,
CCL2↓, CXCL2↓,
CCL11↑, CCL24↑,
CCL1↑, and CCL13↑
Day 14: CCR7− and
CXCR5−
CCL19-induced migration may
be impaired even in the presence
of CCR7.
Ehlin-Henriksson et al.,
2009
DENV human – – Hour 48: CCR7+
mo-DCs↑
Help DENV infect mo-DCs Wu et al., 2009; Hsu
et al., 2015
Influenza A
virus
Mice – – Day 8: CCR7↓ and
α4β7↓ in the lung
parenchyma and
CCR7↑ in the lung
draining lymph node
T cells at different anatomical
sites represent the most
differentiated effector cell type
and lack the ability to recirculate.
Debes et al., 2004
Human Hours 2–4: CXCL16,
CXCL1, CXCL2, and
CXCL3↑
Hours 8–12: CXCL8,
CCL3, CCL4, CCL5,
CXCL9, CXCL10, and
CXCL11↑
Hours 24–48: CCL19,
CCL22, and CXCL13↑
Attract naïve T and B
lymphocytes
Piqueras et al., 2006
HBV Mice – – CCR7+, CD45RA+,
CD127+, and CD8+ T
cells↑
Help chronic infection Zhang et al., 2009; Cao
et al., 2014
WNV Mice – – CCR7+ mDCs↑ Absence of CCR7 results in the
dysregulation of the number of
circulating T cells; CCR7-deficient
mice have a defect in CNS viral
clearance; CCR7 is a gatekeeper
for non-specific viral transference
to the brain.
Bardina et al., 2017
resulting in more severe disease (Le Nouën et al., 2011;
Inchley et al., 2013) (Table 1).
During EBV infection, CCR7 expression likely plays an
important role in pathogenesis. Compared with uninfected
tonsillar B cells, CCR7 expression, which is critical for the
migration of B cells into lymphoid tissues, has been shown to
decline from day 2 after EBV infection and be undetectable by
day 14 (Ehlin-Henriksson et al., 2009) (Table 1). In addition,
migration of EBV-infected cells toward CCL19 or CCL21 is
impaired, although the expression of CCR7 in infected cells is
similar to that in uninfected controls (Ehlin-Henriksson et al.,
2009; Hauser and Legler, 2016; Dunham et al., 2017; Wu et al.,
2017). CCR7 plays an essential role in B cell trafficking in
lymphoid tissue, and its activation has been shown to be strictly
dependent on a highly conserved cellular DNA binding factor
(CBF1) as a blockade of or a deficiency in this factor results in
the repression of immunoglobulin (Ig) expression in the context
of EBV infection (Maier et al., 2005, 2006).
During Influenza A virus infection, the Th1-based immune
response dominates the immune process (Doherty et al., 1997).
CCL19/CCL21 and CCR7 are well-known to be essential for
fulfilling the important role of recruiting T cells into the lung and
other peripheral specialized microenvironments within tissues
(important pathogen entry sites). CCR7 plays an important role
in the migration of T cells from lymph nodes and Peyer’s patches
through high endothelial venules during mucosal immune
protection (Förster et al., 1999; Debes et al., 2004). However,
compared to uninfected mice, CCR7 expression has been shown
to be down-regulated on influenza virus-specific CD4+ T cells
obtained from the spleen, mesenteric lymph nodes (MLNs) and
the lungs at the peak of infection (Debes et al., 2004) (Figure 2),
indicating that these cells lost the ability to recirculate after the
response to viral antigens (Ags).
INCREASED CCR7 EXPRESSION IN THE
CONTEXT OF DENV INFECTIONS
High expression of CCR7 on immunocytes has been observed
in DENV infection. DCs are the most important target cells,
and CCR7 expression has been shown to be increased on
DENV-stimulated mo-DCs (Wu et al., 2011). However, mo-DCs
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 October 2019 | Volume 7 | Article 212
fcell-07-00212 October 1, 2019 Time: 12:59 # 5
Yan et al. Viral Infection-Related Roles of CCL19/CCR7
FIGURE 2 | CCL19 and CCR7 mediate virus antigen uptake and immunocyte activation and differentiation. DC, B and T lymphopoiesis are characterized by
sequential changes in migration properties. Surface receptor and Ig expression occurs during T lymphopoiesis in bone marrow and the thymus during immune
response initiation and the generation of effector T cells for participation in active defense at virus entry sites in peripheral tissues, including blood, lymph, mucosal
venules and MALT; thereby, inflammation and the establishment of memory cells for immune surveillance occur. α4β7, integrin α4β7; LFA-1, lymphocyte
function-associated antigen-1; ASC, antibody-secreting cell; MALT, mucosal-associated lymphoid tissue. Other mucosal compartments: colon, alveolus, mammary
and salivary glands, genital mucosa.
with increased CCR7 expression have a greater opportunity to
interact with abundant T cells and begin to secrete cytokines,
metalloproteinases, and chemokines in the T-zone of draining
lymph nodes. The clinical manifestations of DENV infection
include dengue fever and potentially fatal phenomena, such as
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). The interaction between DENV and target immune
effectors, cytokines or chemokines may lead to the development
of severe clinical manifestations, such as DHF (Wu et al., 2009).
In clinical therapy, some medicines, such as leflunomide, inhibit
the excessive production of cytokines and chemokines from
DENV-infected mo-DCs by suppressing mo-DC maturation
(Wu et al., 2011). Similarly, DENV infection has been shown
to specifically increase the mRNA and protein levels of Gal-
9. Additionally, Gal-9 small interfering RNA downregulates
CCR7 expression and suppresses DENV-specific DC migration
toward the chemoattractants CCL19 and CCL21. Thus, a Gal-
9 inhibitor might be useful for preventing immunopathogenesis
in DENV infection (Hsu et al., 2015). Similar functional
molecules might be useful in drug development to prevent
DENV immunopathogenesis by reducing the number of CCR7-
expressing cells.
CCL19 HELPS ESTABLISH VIRAL
INTEGRATION AND LATENCY AND
DOWN-REGULATES CCR7 EXPRESSION
IN HIV-1 INFECTION
Via interacting with its receptor (CCR7), CCL19 has the potential
to activate the signaling pathway enabling HIV-1 to enter the
nucleus of resting (memory) T cells (Saleh et al., 2016; Cameron
et al., 2010; Anderson J.L. et al., 2016). HIV-1 latent infection
in resting memory CD4+ T cells is a major barrier to HIV-
1 eradication. The reversal of proviral latency has attracted
much attention as a curative strategy for HIV-1 infection
(Cillo et al., 2014). CCL19-treated CXCR4-expressing CD4+ T
cells have been shown to exhibit increased permissiveness for
HIV-1 production, thereby facilitating provirus post-integration
and latency (Anderson J.L. et al., 2016). Furthermore, inoculation
of CD4+ T cells with HIV causes a modest down-regulation
(as shown via flow cytometry) of CCR7 expression and a slight
increase of CCR5 expression after stimulation with CCL19
(Anderson J.L. et al., 2016). CCR5 is a co-receptor essential for
HIV-1 entry into susceptible cells and is an attractive target for
controlling HIV-1 infection (Li et al., 2015). In addition, CCL19
and mDCs co-culture with CD4+ T cells has been shown to be
beneficial for CCR5- and CXCR4-tropic virus latent infection
in vitro (Anderson J.L. et al., 2016).
CCR7 IS REQUIRED FOR THE
SUFFICIENT MIGRATION OF MATURE
DENDRITIC CELLS (mDCs) AND T
CELLS INTO THE DRAINING LYMPH
NODES FOLLOWING VIRAL INFECTIONS
In the context of chronic HBV infection, mDCs are highly
migratory, which is accompanied by the up-regulation of CCR7
expression on hepatic mDCs and an increase in the response to
CCL19 (Abe et al., 2004). In two studies, immature hepatic DCs
did not respond to any tested chemokines, despite the expression
of mRNA transcripts encoding the appropriate receptors for
these chemokines, and CCR7 expression was strongly enhanced
in response to DC maturation (Abe et al., 2004; Thomson and
Knolle, 2010). Hepatic mDCs play a critical role in promoting
immune tolerance by producing IL-10 and TGFβ, activating
regulatory T cells or regulatory B cells and suppressing effector
T cell proliferation (Abe et al., 2004; Liu et al., 2018). Compared
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with the robust responses at clinical onset, HBV-specific CD8+
T cell responses are rather weak and limited, which may lead
to viral persistence and disease progression (Nitschke et al.,
2016; Fisicaro et al., 2017; Wieland et al., 2017). However, acute
inflammation may convert hepatic mDCs from a tolerogenic
phenotype, allowing these cells to activate T cells (Abe et al., 2004;
Thomson and Knolle, 2010).
CCR7 expression can induce the migration of antigen-specific
effector and central memory T cells to the lymph nodes via
the chemotactic response to CCL19 (Abe et al., 2004). The
major phenotype and functions of pathogen-specific CD8+
T cells may differ in different viral infections (Appay et al.,
2002; Romero et al., 2007). The quantitative and qualitative
compositions of the immune cells in the liver markedly differ
from those in secondary lymphoid organs, including the spleen,
lymph nodes and peripheral blood. The hepatic CD8+/CD4+
T cell ratio is 3.5:1; however, this ratio is the reverse of the
1:2 CD8+/CD4+ T cell ratio found in secondary lymphoid
organs (Horst et al., 2016). CD8+ T cells play crucial roles
in HBV control and liver inflammation. Several studies have
investigated CCR7 expression by HBV-specific CD8+ T cells
in the context of chronic HBV infection (Boettler et al., 2006;
Zhang et al., 2009). Up-regulation of programed death-1 (PD-
1) expression can impair HBV-specific memory CD8+ T cell
responses, resulting in the functional suppression of IFN-γ
production. Additionally, blockage of PD-1/PD-L1 interactions
in vitro increases the frequency of HBV-specific CD8+ T
cells, and enhances CCR7, CD45RA, and CD127 expression in
these cells, resulting in increased cell proliferation and IFN-γ
production (Zhang et al., 2009) (Table 1).
Chronic infections with blood-borne pathogens, such as HIV-
1, HBV and HCV, tend to increase the development of memory
homeostasis T cells (Carotenuto et al., 2011; Cao et al., 2014;
Cillo et al., 2014; Baskic et al., 2017). During primary viral
infections, virus-specific T cell responses are vigorous; however,
once a persistent infection is established, both virus-specific
CD4+ and CD8+ T cells become dysfunctional or difficult to
detect ex vivo (Cao et al., 2014). Virus-specific CD8+ effector T
cells play a critical role in eliminating HIV-1, EBV, HBV, CMV
and HCV infections, and the expression patterns of CCR7, CD27,
and CD28 exhibit similar characteristics during the primary
infection phase and chronic phase of a persistent infection
(Appay et al., 2002; Romero et al., 2007). The CCR7+ CD27+,
CCR7− CD27+, and CCR7− CD27− phenotypes can represent
the early, median, and late stages of memory CD8+ T cell
differentiation, respectively, while a down-regulated expression
of these molecules indicates an inability of T cells to differentiate
toward the effector phenotype. Several studies report that the
removal of effector T cells from circulation favors the recruitment
of CCR7+ naïve cells, which may result in an impairment in
the generation of functionally competent memory T cells and an
inability to control viral replication (Appay et al., 2002).
Mature dendritic cells and T cells that express CCR7 enhance
the velocity of T cell locomotion within the lymph nodes and,
thus, increase the likelihood that T cells encounter DCs (Mora
and von Andrian, 2008). In influenza virus infection, high
levels of CCR7+ IFN-γ+ CD4+ T cells have been observed
in lung draining lymph nodes (Debes et al., 2004). A study
investigating the kinetics of chemokine expression showed that
the levels of CCL19, CCL22, and CXCL13 are significantly
up-regulated during the third wave (8 to 24 h) of influenza
virus infection, which helps CCR7+ DCs reach the lymphoid
organs and attract naïve T and B cells (Piqueras et al.,
2006) (Table 1).
The major adaptive immune lymphocytes present in the lungs
of human infants who have died from severe RSV infection
are B cells (Welliver et al., 2007; Reed et al., 2009). The B cell
differentiation factor BAFF is an indicator of pulmonary Ab
responses after HRSV, HMPV, H1N1, bocavirus, rhinovirus and
Mycoplasma pneumoniae infections (McNamara et al., 2013).
CCL19 and other chemokines, particularly CXCL12, CXCL13
and CCL21, influence B cell and human blood DC (i.e.,
plasmacytoid and myeloid DCs) differentiation, migration and
homeostasis (Freire-de-Lima et al., 2017; Alturaiki et al., 2018).
The expression kinetics of these chemokines has been reported
to be related to the airway epithelial innate immune response
to respiratory virus infections. CCL19 has been shown to be
expressed in lung tissues 1, 2, and 7 days after infection with RSV
(Le Nouën et al., 2011; Inchley et al., 2013; Alturaiki et al., 2018).
However, in the context of influenza virus infection, CCL19 and
CCL21 levels have been reported to be increased during the late
wave (Comerford et al., 2006). These variable results may be
explained by differences in the models or sampling methods used
(Alturaiki et al., 2018) (Table 1).
During homeostasis, CCR7 regulates the homing of T
cells into lymphoid organs. During WNV infections, CCR7+
DCs regulate the homing of T cells expressing the cognate
ligands CCL19 or CCL21 into the lymph nodes immediately
following infection and restrict leukocyte migration into the
brain. Leukocyte hypercellularity within the central nervous
system (CNS) contributes to CNS viremia, neuroinflammation,
and increased mortality. Thus, CCR7 acts as a host defense
restriction factor limiting neuroinflammation during acute WNV
infection (Bardina et al., 2017) (Table 1).
Taken together, these data show that host responses to
viral infections involve distinct effectors of innate and adaptive
immunity and that the lymphocyte mobilization mediated by
these effectors needs to be coordinated to ensure protection.
Both inflammatory and homeostatic chemokines are involved
in the control of the trafficking of effector or memory cells.
Inflammatory chemokines determine the cellular infiltrates at
sites of pathogen entry, whereas inflammation and homeostatic
chemokines regulate the inflammation-independent, continuous
trafficking of memory cells through healthy peripheral tissues.
CCL19-CCR7 AXIS SIGNALING
PATHWAYS IN VIRAL INFECTIONS
The CCL19-CCR7 axis is involved in the constitutive migration
and homing of lymphocytes. Furthermore, the CCL19-CCR7
axis has been shown to perform other biological activities,
such as regulation of DC morphologic change and thymic
T cell development and suppression of DC apoptosis,
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which can lead to the regulation of adaptive immunity and
tolerance (Yanagawa and Onoe, 2002; Müller and Lipp, 2003;
Sánchez-Sánchez et al., 2004; Förster et al., 2008; Raju et al.,
2015). This axis performs its biological functions by activation
of the G protein-coupled receptor kinase (GPK)/β-arrestin that
transduces the binding of extracellular stimuli to intracellular
signaling (Zidar et al., 2009; Tian et al., 2014). CCL19 but
not CCL21 induces robust β-arrestin 2 recruitment and
results in serine/threonine-phosphorylated receptor CCR7
internalization to endosomal vesicles, thereby efficiently limits
receptor susceptibility to extracellular ligands (Kohout et al.,
2004) (Figure 1). In addition, CCL19 has been shown to be
more efficient than CCL21 in activating ERK1/2 (part of the
MAP kinase cascade) through Gαi subunit (Kohout et al., 2004;
Raju et al., 2015) and increasing Ca2+ flux through the Gβγ
subunit (Yoshida et al., 1998; Otero et al., 2008) (Figure 3).
CCR7, as a homeostatic chemokine receptor, inhibits adenylate
cyclase, and limits the level of intracellular cyclic adenosine
monophosphate (cAMP) and the activation of protein kinase
A (PKA) (Steen et al., 2014; Raju et al., 2015). Similar to other
GPCRs, CCR7 plays a crucial role in activating or inhibiting
downstream signaling adaptors in viral infections through
G-protein-promoted secondary messengers, including cAMP,
Ca2+, and phosphoinositides (Steen et al., 2014; Raju et al., 2015)
(Figure 3). The following three principle modes are involved
in the GPCR homeostatic regulation: desensitization (receptor
becomes refractory to continued stimuli), internalization
(receptors are physically removed from the cell surface by
endocytosis) and down-regulation (cellular receptor levels are
decreased) (Tian et al., 2014). In addition to inducing directional
steering in cells, CCR7 provides costimulatory and survival cues
(Bock et al., 2016). Moreover, CCR7-mediated human T cell
polarization and migration have been shown to be linked to
protein–protein interactions in cell signaling across multiple
cellular compartments (Raju et al., 2015).
Over the past few years, numerous CCL19-based signaling-
related adaptor molecules have been reported in CCR7 signaling
pathways, and their specific functions during viral infections are
summarized in Figure 3. Viruses have been well-demonstrated
to have highly efficient strategies to modulate and prevent the
transduction of apoptotic signals to favor their infections through
viral proteins, such as the HBx gene product of HBV (Shin et al.,
FIGURE 3 | CCL19 and CCR7 signaling pathways. During viral infections, many studies have supported the notion that the interaction between CCL19 and CCR7
facilitates the up-regulation/down-regulation of downstream signaling adaptor molecules and results in anti-apoptosis, cell survival, cytokine production, cellular
growth, differentiation, chemotaxis, and migration, etc. KSHV, Kaposi sarcoma-associated herpesvirus; HTLV, human T-cell leukemia virus 1; HPV, human
papillomavirus.
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2016). For this review, we searched CCR7-associated chemokine
signaling pathways in the KEGG PATHWAY Database1 and
discuss the multiple regulatory mechanisms of CCR7 signaling
and the influences on CCR7 functions during viral infections.
The HIV-1 accessory protein Vpu reduces CCR7 expression
on CD4+ T cells (Ramirez et al., 2014). Vpu specifically interacts
and colocalizes with CCR7 in the trans-Golgi network in which
CCR7 is retained. The stimulation of HIV-1-infected primary
CD4+ T cells with CCL19 reduces mobilization of Ca2+, reduces
phosphorylation of Erk1/2, and impairs migration toward
CCL19 (Ramirez et al., 2014). Studies concerning CCL19-CCR7
signaling have shown that CCL19-induced signaling proteins
mediate HIV-1 integration in CD4+ T cells at several integration
sites and that this process is suppressed by inhibitors of the PI3K,
NF-κB and MEK/Ras/Raf signaling pathways (Raju et al., 2015;
Saleh et al., 2016) (Figure 3). Recently, the Food and Drug
Administration (FDA) approved the Janus Kinase (JAK) inhibitor
ruxolitinib to diminish the release of multiple cytokines and
thereby prevent their effects on latency reversal in HIV-1-positive
patients. A combination of ingenol compounds with the JAK
inhibitor may represent a novel strategy for HIV-1 eradication
(Spivak et al., 2016).
The infection of DCs with DENV causes cell maturation
and probably enhances cell migration to lymphoid organs
to promote interactions with T cells (Mathew and Rothman,
2008). At 48 h post-infection, the number of CCR7+ mo-DCs
increases, and the increase in cell number is accompanied by
the significant activation of the COX-2-PGE2 signaling pathway
in migrating DCs (Wu et al., 2009). All MAPK inhibitors and
the COX-2 inhibitor celecoxib suppress DENV-induced PGE2
production to basal levels. The mechanisms involved in the
activation of COX-2 include the activation of the IKK-NF-
κB and MAPK-activator protein-1 (AP-1) signaling pathways
(Wu et al., 2009; Hsu et al., 2015). Several COX-2 upstream
signaling molecules have been suggested to be useful for the
treatment or control of viral infections. For example, the blockade
of ERK, which is upstream of the MKK1/2 kinase, suppresses
virus infectivity by inhibiting early gene expression in human
CMV (hCMV) infections (Johnson et al., 2001). Additionally,
leflunomide has been shown to be an effective therapeutic drug
for DENV infection. Leflunomide inhibits DENV-induced mo-
DC migration in response to the chemoattractant CCL19 by
suppressing CCR7 expression and the NF-κB and AP-1 signaling
pathways (Wu et al., 2011).
CCL19 AS A MOLECULAR ADJUVANT
ENHANCES VIRUS-SPECIFIC IMMUNE
RESPONSES
Cytokines have been successfully used as molecular adjuvants to
promote virus-specific humoral and cellular immune responses
by modifying the magnitude, intensity, nature, and duration
of the responses (Sin et al., 1999; Kanagavelu et al., 2012;
Gupta et al., 2015; Doosti et al., 2019). The positive effects
1https://www.kegg.jp/kegg-bin/show_pathway?ko04062+K04182
of chemokines as immunomodulators of vaccines against viral
infections remain to be further evaluated. CCL19 has been
postulated as a promising adjuvant candidate for vaccines against
both cancers and infectious diseases due to its paramount
importance in immune response formation and its diverse effects
on DC and lymphocyte migration and activation. CCL19 also
controls lymphocyte localization during T cell development in
response to immunization. Activated T cells lead to alterations
in the expression of various molecules, including integrins
(α4β3, LFA-1), selectins, and chemokine receptors, leading to the
modulation of key intracellular signaling events that promote
T cell proliferation, differentiation, and migration to inflamed
tissues (Murdoch and Finn, 2000; Tahamtan et al., 2018; Justo-
Junior et al., 2019) (Figure 2).
In the context of viral neutralizing antibodies (nAbs), studies
have shown that both monomeric gp120 and trimeric gp140
HIV-1 vaccines induce neutralizing antibody responses but still
lack sufficient breadth to effectively protect against diverse
HIV-1 isolates (García-Arriaza et al., 2017; Shen et al., 2017).
HSV-2 gB or gD subunit vaccines could induce high levels of
neutralizing Abs but could not efficiently protect mice against a
viral challenge (Zhu et al., 2014). Thus, effective vaccines may
be needed to broadly induce neutralizing Abs. DNA vaccines are
generally considered suboptimal for inducing humoral responses,
particularly in humans. Strategies to overcome these limitations
include the optimization of plasmid backbones, the use of
molecular adjuvants and changing the delivery methods. We
previously explored the possibility that the use of chemokine
CCL19 or CCL28 could optimize systemic and mucosal humoral
responses to a HIV-1 vaccine candidate gp140, which is the
primary target of Ab-mediated antiviral functions (Hu et al.,
2013). In the CCL19 adjuvant group, CCR7 showed a high
expression on activated B cells, T cells and DCs in secondary
lymphoid organs, which was beneficial for increasing the chance
of interactions among B cells, T cells, and DCs in the local
tissue (Table 2).
In the context of cellular immune responses, several potential
roles of molecular adjuvants, such as cytokines and costimulatory
molecules, in vaccination strategies have been investigated.
Currently, various promising prophylactic vaccines focused
on inducing substantial vaccine-specific T cell responses have
been developed (Hartoonian et al., 2014; Rosendahl Huber
et al., 2014). Increased breadth in the vaccine-induced T
cell response has been found to be beneficial against many
chronic pathogens (Kallas et al., 2016; Panagioti et al., 2016).
The molecular adjuvant CCL19 plays an important role in
augmenting the trafficking of T cell-based vaccines into regional
T cell compartments through efficient CCR7 gene transduction
and participates in the priming and preparation of antigen-
specific T cells and the production of Abs (Müller and Lipp, 2003;
Aritomi et al., 2010).
In chronic viral infections, memory B and T cells are more
numerically and functionally superior to neutralizing antibodies
than the corresponding naïve precursor cells that are present
before infection as memory lymphocytes tend to induce rapid and
powerful recall responses (Panagioti et al., 2016, 2018). Because
neutralizing antibodies fail to provide control over persisting viral
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infections (e.g., herpesviruses, HIV-1, and HCV), therapeutic
immunizations should focus on generating strong cellular T cell-
based immunity and more virus-specific memory immunocytes.
Live attenuated, synthetic and subunit vaccines are all able to
elicit central memory T cells, effector memory T cells and resident
memory T cells, and these responses are highly dependent
on the addition of adjuvants and the route of administration
(Schaerli and Moser, 2005; Mueller et al., 2013; Khan et al., 2017;
Gebhardt et al., 2018).
Substantial evidence indicates that CCL19-adjuvanted vaccine
recipients produce CD4+/CD8+ T cells more promptly and
at higher levels than recipients administered a control vector
lacking CCL19 (Table 2). In a study coadministering HSV-1
vaccine and plasmids encoding CCL19 (pCCL19) and HSV-1
gB (pgB), CCR7high DCs were activated and migrated, resulting
in the enhancement of antigen uptake and presumably the
augmentation of naïve T cell priming. Compared with pCCL19
delivered alone, the codelivery of pCCL19 and pgB induced a
notable increase in lung CD11c+ DCs. In the pCCL19-codelivery
group, the CD8+ T cells isolated from the lungs produced more
IFN-γ. Consistently, it appears that CCL19 codelivery may lead
to the induction of functional memory CD8+ T cells (Lee et al.,
2003; Toka et al., 2003). The high level of IFN-γ observed in these
CD8+ T cells may suggest that the enhanced potential to secrete
IFN-γ plays a notable protective role in lethal mucosal HSV-1
challenges. In our HIV-1 and HSV-2 vaccine studies, adjuvant
CCL19 codelivery produces a balanced enhancement of HIV-1
gp140- or HSV-2 gB-specific Th1/Th2 responses (Hu et al., 2013;
Yan et al., 2015). Such enhancements appear to be associated with
the mobilization of abundant CCR7+ immunocyte migration
to secondary lymphoid organs and mucosal tissue. Similarly, a
previous HCV vaccine study showed that CCL19 contributes
to the activation of DCs and CD4+ T cells, enhances CD8+
T cell accumulation and helps attract rare virus-specific T
cells in the context of HCV core DNA vaccination in mice
(Hartoonian et al., 2014). CCL19 as molecular adjuvant is helpful
in increasing the naïve T cell sensitivity to low density Ag
presentation. Such functional studies might be helpful for human
virus vaccine development.
Regarding virus challenges, whether enhanced immunity
mediated by adjuvant CCL19 can protect animals against genital
tract mucosal infections has been tested, and previous studies
have demonstrated that CCL19 enhances the protective responses
to an HSV-1 challenge (Lee et al., 2003; Toka et al., 2003). In
these studies, a CCL19 protective vaccination regimen was shown
to elicit increased serum and vaginal HSV-1 gB-specific IgG
and IgA Ab levels through intranasal mucosal immunization.
CCL19 appeared to play a pivotal role in increasing Ab responses
(levels of total Abs, virus-specific Abs and neutralizing Abs).
Furthermore, CCL19 enhanced gB-specific immune responses by
improving the kinetics and distribution of the adaptive immune
response to the codelivered antigen and protected animals against
genital infection by HSV-2. Finally, the results showed that the
fusion constructs induced strong HSV-2 gB-specific IgG and
IgA Ab levels in mouse sera and vaginal fluids. In a different
study, we revealed that a gB-CCL19 fusion construct exhibited a
stronger ability to increase the numbers of CCR7+ immunocytes
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 October 2019 | Volume 7 | Article 212
fcell-07-00212 October 1, 2019 Time: 12:59 # 10
Yan et al. Viral Infection-Related Roles of CCL19/CCR7
in secondary lymphoid tissue and IgA+ cells in mucosal sites
(Figure 2). The enhanced systemic and vaginal mucosal Abs
protected the tested mice against a lethal intravaginal HSV-2
challenge in vivo (Yan et al., 2015). These findings may provide
an effective strategy for the design of vaccines against mucosal
infection by sexually transmitted viruses.
CONCLUSION AND PERSPECTIVES FOR
CCL19 USE FOR THE PREVENTION OF
VIRAL INFECTIONS
This review seeks to address how we can apply the current
understanding of CCL19 and CCR7 functions to better
understand the pathogenesis of viral infections and better treat
or prevent viral diseases. CCL19 and CCR7 are essential players
in the balance between immunity and tolerance. CCL19 promotes
activation-induced cell death (AICD) in antigen-specific CD4+ T
cells, and this chemokine regulates not only T cell mobilization
but also the post-activation fate of T cells (Yasuda et al., 2007;
Förster et al., 2008). It is a key step to understanding the
appropriate initial programing signals as the signaling pathways
of CCR7 elicited by CCL19 during priming or boosting influences
the development of lymphocytes. Information regarding the
differences in anatomical location, activation, and differentiation
between memory T cells in lymphoid organs and those in non-
inducing lymphoid organs could also be very valuable (Thomson
and Knolle, 2010). We believe that recent advances in the field of
target cell signaling stimulation coupled with animal models that
express viral antigens could provide an opportunity to directly
address some of these questions in a living animal. Such work
will not only improve our understanding of CCL19 and CCR7
expression and their functions during viral infections but may
also provide tools for the design of new therapeutic strategies
for the treatment of viral infections and the prevention of
invading pathogens.
Several lymphocyte-targeted chemokines, such as CCL19,
CCL21 and CCL28, are known to be important for regulating
adaptive immune responses during viral infection, and their
engagement with cognate receptors can result in enhanced T cell
activation, expansion, and survival as well as the establishment of
long-term memory. The most important feature of the immune
system is its ability to produce protective immune responses
against pathogens while maintaining tolerance to self-antigens
and innocuous environmental Ags. Therefore, chemokines
have the potential to serve as effective immunomodulatory
components of prophylactic vaccines against chronic viruses
(Hartoonian et al., 2014; Kallas et al., 2016).
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